SRPT Sarepta Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SRPT

Price (delayed)

$17.26

Market cap

$1.82B

P/E Ratio

28.77

Dividend/share

N/A

EPS

$0.6

Enterprise value

$2.39B

?
Relative Growth: Rel. Growth: 78
Relative Strength: Rel. Strength: 30
Relative Valuation: Rel. Valuation: 72
Relative Profitability: Rel. Profitability: 54

Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going ...

Highlights
The net income has soared by 126% YoY and by 109% QoQ
The EPS has soared by 124% YoY and by 108% from the previous quarter
SRPT's gross profit is down by 25% year-on-year
Sarepta Therapeutics's gross margin has decreased by 23% YoY
Sector: Healthcare
Industry: Biotechnology
Website: https://www.sarepta.com/
Peers: GILD NVAX PTCT BCRX

Key stats

What are the main financial stats of SRPT

SRPT stock price

How has the Sarepta Therapeutics stock price performed over time
Intraday
-2.21%
1 week
9.38%
1 month
2.74%
1 year
-8.53%
YTD
-19.8%
QTD
-20.68%

Financial performance

How have Sarepta Therapeutics's revenue and profit performed over time
Revenue
$2.18B
Gross profit
$1.37B
Operating income
-$40.96M
Net income
$65.06M
Gross margin
62.9%
Net margin
3%
SRPT's net margin has surged by 127% year-on-year and by 109% since the previous quarter
The net income has soared by 126% YoY and by 109% QoQ
SRPT's operating income has soared by 94% since the previous quarter and by 65% year-on-year
SRPT's operating margin has soared by 94% from the previous quarter and by 63% YoY

Price vs fundamentals

How does SRPT's price correlate with its fundamentals

Growth

What is Sarepta Therapeutics's growth rate over time

Valuation

What is Sarepta Therapeutics stock price valuation
SRPT P/E details
P/E
28.77
P/B
1.2
P/S
0.83
EV/EBIT
97.86
EV/EBITDA
28.94
EV/Sales
1.1
The EPS has soared by 124% YoY and by 108% from the previous quarter
SRPT's P/B is 89% below its 5-year quarterly average of 10.9 and 20% below its last 4 quarters average of 1.5
The company's equity rose by 32% QoQ and by 32% YoY
The P/S is 89% less than the 5-year quarterly average of 7.5 and 8% less than the last 4 quarters average of 0.9
The revenue fell by 2.2% YoY

Efficiency

How efficient is Sarepta Therapeutics business performance
The ROA has soared by 128% YoY and by 109% from the previous quarter
The return on equity has surged by 125% year-on-year and by 109% since the previous quarter
Sarepta Therapeutics's ROIC has soared by 119% YoY and by 104% from the previous quarter
The ROS has soared by 115% YoY and by 103% from the previous quarter

Dividends

What is SRPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SRPT.

Financial health

How did Sarepta Therapeutics financials performed over time
The total assets is 90% more than the total liabilities
The company's current ratio has surged by 100% QoQ and by 15% YoY
Sarepta Therapeutics's quick ratio has soared by 72% from the previous quarter and by 8% YoY
SRPT's debt is 31% smaller than its equity
The debt to equity has declined by 42% year-on-year and by 23% since the previous quarter
The company's equity rose by 32% QoQ and by 32% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.